The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs. Representing a range of perspectives within the drug development process, these distinguished academics are experienced pre-clinical and clinical investigators, medical oncologists, statisticians, and immunologists, who have experience working within regulatory agencies, the pharmaceutical industry and patient advocacy. The chairperson and directors are elected for a period of three years. The CDDF board of directors aim to speed up and optimise drug development programmes and avoid suboptimal drug development strategies.
CDDF BOARD OF DIRECTORS
- Prof. John Smyth – Chairperson
- Prof. Ruth Plummer –Deputy Chairperson
- Prof. Axel Glasmacher – Treasurer
- Prof. Jaap Verweij – Managing Director
- Prof. Francesco De Lorenzo
- Prof. Eva Skovlund
- Prof. Catarina Edfjäll
CDDF OFFICE
- Prof. Jaap Verweij – Managing Director
- Marjorie Recorbet -Director of Operations
- Hyunmin Park – Projects Coordinator
CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.